Education > XRAY > Search Results

FORCE's eXaming the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

41 through 50 of 212

Relevance: High

pointerRelevance

Strength of Science: Medium

pointerStrength of Science
View Related Clinical Trials

Study : How does a breast cancer diagnosis affect employment of young women?

Most relevant for: Young women with breast cancer

Most young women who are diagnosed with breast cancer remain employed one year after their diagnosis. Among breast cancer patients who were unemployed a year later, half reported that their unemployment was due to health issues. The issues that were most associated with unemployment were stage of cancer and financial stress prior to diagnosis. (1/10/20)

Read More
How does a breast cancer diagnosis affect employment of young women?

Relevance: Medium-High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : A new breast cancer drug improves overall survival among people with brain and other metastases

Most relevant for: People with metastatic breast cancer

A promising new drug called tucatinib combined with standard therapy shows benefit for women with HER2-positive metastatic breast cancer. Women who took tucatinib experienced longer progression-free survival (time before their cancer worsened), longer overall survival time and response of cancer (shrinking or disappearing). Strikingly, better outcomes were also seen for women with brain metastases, which is often difficult to treat. (12/20/19) 

THIS INFORMATION HAS BEEN UPDATED on 04/17/20:  The U.S. Food and Drug Administration has approved Tukysa (tucatinib) for use in combination with trastuzumab (Herceptin) and capecitabine for patients with advanced or metastatic HER2-positive breast cancer, including patients with brain metastases (disease that has spread to the brain). Patients who have received one or more treatments targeting Her2 in the metastic setting are eligible to receive Tukysa. Tukysa  is an oral (tablet) tyrosine kinase inhibitor which is taken twice daily. 

 

 

Read More
A new breast cancer drug improves overall survival among people with brain and other metastases

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Women who exercise have lower breast cancer risk whether or not they have a family history of breast cancer

Most relevant for: Young, high risk women

The effect of physical activity on breast cancer risk was looked at  in a study of over 15,000 women. The results suggest that exercise lowers breast cancer risk regardless of family  history of breast cancer or menopausal status.  (12/6/19)

Este artículo está disponible en español.

Read More
Women who exercise have lower breast cancer risk whether or not they have a family history of breast cancer

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : Genetic causes of hereditary pancreatic cancer: BRCA and beyond

Most relevant for: People diagnosed with pancreatic cancer

An update on hereditary pancreatic cancer presented at the annual American Society of Clinical Oncology meeting covered genes and lifetime risk. The update emphasized that all pancreatic cancer patients should be offered genetic counseling and testing. Genetic test results may impact treatment, screening for other cancers and risk to family members. (11/26/19)

Read More
Genetic causes of hereditary pancreatic cancer: BRCA and beyond

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : A new blood test may help predict early-stage breast cancer patients at highest risk for recurrence

Most relevant for: People with early-stage breast cancer

Which patients are at risk for a relapse of early-stage breast cancer? Tests to predict recurrence would help find people who need more monitoring after treatment and provide a chance to find and treat them earlier. This study looked at whether a blood test for tumor DNA (called circulating tumor DNA or ctDNA) is useful for finding people with recurrence earlier than current clinical practice. (11/4/19)

Este artículo está disponible en español.

Read More
A new blood test may help predict early-stage breast cancer patients at highest risk for recurrence

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

Most relevant for: Women newly-diagnosed with ovarian cancer

This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)

Read More
Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

Relevance: Medium-Low

pointerRelevance

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Personal Story : A “flu shot” against breast cancer? Not so fast

Most relevant for: Women diagnosed with Ductal Carcinoma In Situ (DCIS)

There have been multiple reports in the media of a Florida woman who had a "shot" to treat her DCIS with a promising outcome. This XRAY reviews the underlying story about this early breast cancer vaccine trial. (10/25/19)

Read More
A “flu shot” against breast cancer? Not so fast

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Personal Story : Running marathons with metastatic breast cancer? Yes!

Most relevant for: Women with metastatic breast cancer

Runner’s World Magazine featured Sarah Smith, a metastatic breast cancer patient who runs marathons and ultra-marathons. By telling her story, Sarah wants to encourage people to stay active, despite the challenges that life may bring. (10/13/19)

Read More
Running marathons with metastatic breast cancer? Yes!

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising

Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation

The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)

Read More
Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Inherited mutations in metastatic breast cancer patients

Most relevant for: People with metastatic breast cancer

Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)

Read More
Inherited mutations in metastatic breast cancer patients